Login to Your Account



Aussie biotech Imugene leads pack in HER2-targeting B-cell immunotherapies

By Tamra Sami
Staff Writer

Friday, January 19, 2018

PERTH, Australia – Australia's Imugene Ltd. could be the first biotech out of the gate in developing B-cell peptide vaccines in the immune-oncology space.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription